Datapoint: FDA Approves Host of Vyvanse Generics

As the nationwide Adderall shortage continues, the FDA last week approved the first generic versions of Takeda’s blockbuster ADHD drug Vyvanse (lisdexamfetamine dimesylate). Manufacturers of the newly approved generics include Actavis, Mylan, Sun Pharmaceutical and Teva. For the treatment of ADHD, Vyvanse holds covered or better status for 88% of all insured lives under the pharmacy benefit. About 43% of lives have preferred access to Vyvanse without utilization management restrictions.

SOURCE: MMIT Analytics, as of 8/31/23

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 24

Datapoint: Florida Adds Three More MCOs to Medicaid Program

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 23

Datapoint: Rhode Island Awards Medicaid Contracts

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 22

Datapoint: Georgia Medicaid Work Program Sees Slow Start

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today